Cancer Imaging最新文献

{"title":"Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study.","authors":"Stephan M Korn, Zhiyu Qian, Hanna Zurl, Nathaniel Hansen, Klara K Pohl, Daniel Stelzl, Filippo Dagnino, Stuart Lipsitz, Jianyi Zhang, Adam S Kibel, Caroline M Moore, Kerry L Kilbridge, Shahrokh F Shariat, Stacy Loeb, Hebert Alberto Vargas, Quoc-Dien Trinh, Alexander P Cole","doi":"10.1186/s40644-025-00898-6","DOIUrl":"10.1186/s40644-025-00898-6","url":null,"abstract":"<p><strong>Background: </strong>Potential rural-urban differences in prostate cancer care are understudied, particularly regarding the utilization of advanced diagnostic tests. Herein we examined variations in Positron Emission Tomography (PET) utilization for prostate cancer care, including diagnosis, staging and treatment planning, across residential regions in the United States.</p><p><strong>Methods: </strong>Patients newly diagnosed with prostate cancer between 2019 and 2021 and post-diagnostic PETs were identified using full Medicare claims data. PET use was assessed in all newly diagnosed patients, though indications vary by risk. Patients' counties were categorized as metro, urban, or rural, from most to least urbanized. Regional PET utilization was further examined at the level of hospital referral regions. A multivariable logistic regression model was performed to assess the impact of rurality on PET imaging. A secondary analysis included an interaction term for race to explore the effect of residence on PET imaging by racial group.</p><p><strong>Results: </strong>Overall, 495 865 patients were included in the analysis: 393 861 (79.4%) lived in metro, 56 698 (11.4%) in urban and 39 707 (8.0%) in rural counties. Patients in metro counties underwent PET imaging more often (8.4%) than patients in urban (7.3%) or rural counties (7.2%), p < 0.0001. At a level of hospital referral region, PET utilization rates ranged from 2.2 to 20.8%. PET imaging was more commonly performed in White compared to Black or Hispanic patients. Rural patients were less likely to undergo PET imaging compared to metro patients (odds ratio [OR] 0.87, 95% Confidence interval [CI]: 0.82-0.92 p < 0.0001). Rural Black (OR 0.69, 95%CI 0.57-0.83, p < 0.0001) and rural White patients (OR 0.89, 95%CI 0.83-0.94 p < 0.0001) were less likely to obtain PET imaging compared to their metro counterparts, p-interaction < 0.0001.</p><p><strong>Conclusion: </strong>Rural patients were less likely to undergo PET imaging than metro patients. The effect of rurality was most pronounced among Black patients. Our findings underscore the need for strategies to support equitable use of PET imaging.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"86"},"PeriodicalIF":3.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study.","authors":"Mengge He, Rahul Singh, Mandi Wang, Grace Ho, Esther M F Wong, Keith W H Chiu, Anthony K T Leung, Ka Yu Tse, Philip P C Ip, Andy Hwang, Lujun Han, Elaine Y P Lee","doi":"10.1186/s40644-025-00906-9","DOIUrl":"10.1186/s40644-025-00906-9","url":null,"abstract":"<p><strong>Objective: </strong>Platinum resistance carries poor prognosis in epithelial ovarian carcinoma (EOC). This study aimed to assess the value of radiomics model based on contrast-enhanced CT (ceCT) in predicting response to platinum-based chemotherapy in EOC.</p><p><strong>Materials and methods: </strong>Patients with histologically confirmed EOC and pre-treatment ceCT were retrospectively recruited from 5 centres. All patients underwent standard platinum-based chemotherapy and optimal cytoreduction. Platinum sensitivity was determined by whether it recurred within six months after platinum-based chemotherapy. The whole tumour volume was manually segmented on the baseline ceCT. Radiomics features were extracted using the open-source package PyRadiomics (version 3.0.1). Patients from centres A-C were randomly divided into training and internal validation sets in 4:1 ratio. Patients from the centres D and E were assigned as independent external validation sets. Spearman's rank correlation followed by 5-fold stratified cross validation (SCV) elastic net repeated for 100 times, and Mann-Whitney U test were deployed for feature reduction and selection. Adaptive synthetic sampling was applied to minimize class biases. Extra Trees classifier across 10-fold SCV was used for model building. The area under curve (AUC), calibration curve assessment, and decision curve analysis (DCA) were deployed to evaluate model performance and translational clinical utility.</p><p><strong>Results: </strong>Seven hundred and three EOC patients (51.6 ± 9.3 years) were recruited. The training data (n = 608) yielded the following classification metrics: AUC (0.917), sensitivity (83.9%), specificity (94.4%), and accuracy (91.7%) in the internal validation set. The external validation set using centre D (n = 44) had AUC (0.877), sensitivity (76.5%), specificity (92.6%), and accuracy (86.4%); while centre E (n = 51) had AUC (0.845), sensitivity (73.3%), specificity (86.1%), and accuracy (82.4%) in predicting platinum sensitivity. DCA illustrated net clinical benefit in internal validation set and both external validation sets.</p><p><strong>Conclusions: </strong>The proposed CT-based radiomics model could be useful in predicting platinum sensitivity in EOC with potential in guiding personalized treatment in EOC.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"85"},"PeriodicalIF":3.5,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12225207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorescence imaging of MALAT1 expression using a Cy5.5-labeled antisense oligonucleotide in lung cancer and epidermal carcinoma cells.","authors":"Zhenfeng Liu, Chengjun Yao, Haopeng Ni, Guolin Wang, Mengjie Dong","doi":"10.1186/s40644-025-00903-y","DOIUrl":"10.1186/s40644-025-00903-y","url":null,"abstract":"<p><strong>Background: </strong>The long noncoding RNA Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) has been extensively studied as an oncogenic factor. Antisense oligonucleotides (ASOs) labeled with the Cyanine5.5 (Cy5.5) dye enable effective in vivo imaging using near-infrared fluorescence.</p><p><strong>Methods: </strong>Pan-cancer research on MALAT1 expression levels was conducted through The Cancer Genome Atlas (TCGA) database analysis. The selectivity and specificity of MALAT1-ASO were validated in lung cancer and epidermal carcinoma cell lines (A549, A431, PC9GR, and PC9) using cellular fluorescence and flow cytometry. Corresponding xenograft models were created for these cell lines, and near-infrared fluorescence imaging assessed tumor imaging effectiveness and the biodistribution of Cy5.5-labeled MALAT1 ASOs.</p><p><strong>Results: </strong>MALAT1 expression levels were found to be upregulated in various tumors and high MALAT1 expression level correlated to poor prognosis in some tumors. The high expression of MALAT1 was confirmed in tumor cell lines. In vitro fluorescent intensity correlated with MALAT1 expression within cells. The fluorescence intensity also exhibited concentration dependence. In vivo experiments revealed a significant contrast between tumor tissues and normal tissues within 24 h. Tumors exhibited varied probe uptake corresponding to their MALAT1 expression levels. Ex vivo experiments shows high probe uptake in kidney, liver and intestine tissues.</p><p><strong>Conclusion: </strong>MALAT1 is highly expressed in various cancer tissues and associated with poor prognosis. In xenograft models of lung cancer and epidermal carcinoma cell lines A549, A431, PC9GR, and PC9, Cy5.5-labeled ASOs exhibit evident binding specificity and discernible imaging effect in both in vitro and in vivo, effectively reflecting MALAT1 expression levels in tumors.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"82"},"PeriodicalIF":3.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of threshold growth for the diagnosis of hepatocellular carcinoma using LI-RADS.","authors":"Jae Seok Bae, Jeong Min Lee, Jeong Hee Yoon, Jae Hyun Kim, Sun Kyung Jeon, Jeongin Yoo","doi":"10.1186/s40644-025-00902-z","DOIUrl":"10.1186/s40644-025-00902-z","url":null,"abstract":"<p><strong>Background: </strong>The utility of threshold growth (TG) in hepatocellular carcinoma (HCC) imaging remains contentious across major guidelines. This study aimed to investigate the diagnostic implications of TG in HCC diagnosis using the criteria set by the Liver Imaging Reporting and Data System (LI-RADS).</p><p><strong>Methods: </strong>In this single-center retrospective study, three radiologists independently evaluated pre-transplantation hepatobiliary agent-enhanced MR images and prior CT/MR images using LI-RADS v2018 in consecutive patients who underwent liver transplantation between January 2010 and November 2022. TG was defined as a ≥ 50% size increase in ≤ 6 months. Explanted livers served as reference standards. Frequencies of TG between HCCs and non-HCCs were compared using Fisher's exact test, and interobserver agreement was assessed using Fleiss κ statistics. The diagnostic performance of LI-RADS category 5 in the diagnosis of HCC was assessed with and without considering TG as a major feature. McNemar tests were used to compare results.</p><p><strong>Results: </strong>The cohort included 158 patients (mean age, 59.1 ± 7.5 years; 130 males) with 280 observations (207 HCCs, 5 non-HCC malignancies, and 68 benign lesions). TG was identified in 44 (15.7%) observations. Interobserver agreement on TG was moderate (κ = 0.280). Incorporating TG as a major feature significantly enhanced the sensitivity of LI-RADS category 5 in diagnosing HCC (33.8% vs. 40.6%, p < 0.001) without compromising specificity (100.0% vs. 94.5%, p = 0.125).</p><p><strong>Conclusions: </strong>Incorporating TG as a major criterion in LI-RADS category 5 enhanced the diagnostic sensitivity for HCC in liver transplant candidates with minimal impact on specificity. However, TG demonstrated a variable interobserver agreement.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"84"},"PeriodicalIF":3.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12217194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a novel clinical-radiological-pathological scoring system for preoperative prediction of extraprostatic extension in prostate cancer: a multicenter retrospective study.","authors":"Liqin Yang, Pengfei Jin, Ximing Wang, Zhiping Li, Huijing Xu, Yongsheng Zhang, Feng Cui","doi":"10.1186/s40644-025-00905-w","DOIUrl":"10.1186/s40644-025-00905-w","url":null,"abstract":"<p><strong>Objective: </strong>To develop and validate a multimodal scoring system integrating clinical, radiological, and pathological variables to preoperatively predict extraprostatic extension (EPE) in prostate cancer (PCa).</p><p><strong>Methods: </strong>This retrospective study included 667 PCa patients divided into a derivation cohort and two validation cohorts. Evaluated parameters comprised prostate-specific antigen density (PSAD), curvilinear contact length (CCL), lesion longest diameter (LD), National Cancer Institute EPE grade (NCI_EPE), International Society of Urological Pathology grade (ISUP), and other relevant variables. Independent predictors were identified through univariate and multivariate regression analysis to construct a logistic model. Coefficients from this model were then weighted to establish a scoring system. The predictive performance of the NCI_EPE, logistic model, and scoring system was systematically evaluated and compared. Finally, the scoring system was stratified into four distinct risk categories.</p><p><strong>Results: </strong>Multivariate analysis identified NCI_EPE, PSAD, CCL/LD, and ISUP as independent predictors of EPE. In the derivation and validation cohorts, the scoring system demonstrated robust predictive accuracy for EPE, with AUCs of 0.849, 0.830, and 0.847, respectively. These values outperformed the NCI_EPE (Derivation cohort: 0.849 vs. 0.750, P < 0.003, Validation cohort 1: 0.830 vs. 0.736, P = 0.138, Validation cohort 2: 0.837 vs. 0.715, P = 0.003) and were comparable to the logistic model (Derivation cohort: 0.849 vs. 0.860, P = 0.228, Validation cohort 1: 0.830 vs. 0.849, P = 0.711, Validation cohort 2: 0.837 vs. 0.843, P = 0.738). Decision curve analysis revealed higher net clinical benefit for both the scoring system and logistic model compared to the NCI_EPE. Risk stratification using the scoring system categorized patients into four tiers: low (0-3), intermediate-low (4-6), intermediate-high (7-9), and high risk (10-12) with corresponding mean EPE probabilities of 9.9%, 26.0%, 52.0%, and 85.0%. These probabilities closely aligned with observed pT3 incidences in the derivation and validation cohorts.</p><p><strong>Conclusions: </strong>The scoring system provides enhanced predictive accuracy for EPE, preoperatively stratifying patients into distinct risk categories to facilitate personalized therapeutic strategies.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"83"},"PeriodicalIF":3.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12220475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging-derived biomarkers from ⁶⁸Ga-DOTATOC PET/CT scans to predict survival of patients with neuroendocrine tumors after PRRT with ¹⁷⁷Lu-DOTATATE.","authors":"Stephan Raad, Ali Al-Fatlawi, C Louise Wise, Christian Fottner, Simin Schadmand-Fischer, Mathias Schreckenberger, Matthias M Weber, Thomas J Musholt, Michael Schroeder, Matthias Miederer","doi":"10.1186/s40644-025-00899-5","DOIUrl":"10.1186/s40644-025-00899-5","url":null,"abstract":"<p><strong>Background: </strong>Neuroendocrine tumors have increased in prevalence and diversity in recent years and are often diagnosed at metastatic stages. Compared with nonradioactive systemic treatment with somatostatin analogs, peptide receptor radionuclide therapy (PRRT) has shown superior overall survival benefits for well-differentiated neuroendocrine tumor patients. This study aimed to identify biomarkers from ⁶⁸Ga‒DOTATOC PET/CT scans to predict survival in patients treated with PRRT in the clinic.</p><p><strong>Methodology: </strong>This retrospective study analyzed ⁶⁸Ga-DOTATOC PET/CT data from 67 NET patients undergoing PRRT. Tumor volumes and SUV metrics were segmented using standardized protocols. Radiomics features from liver metastases were extracted and preprocessed for analysis. Data were analysed via Kaplan-Meier, Cox regression, and PCA to evaluate the prognostic value of volumetric-, radiomics-, and clinicopathological parameters.</p><p><strong>Results: </strong>This study included scans from 67 patients with an average age of 67 years. The mean survival time was 46.5 months, with 43% of patients alive or lost to follow-up at the conclusion of data collection. Despite comprehensive analyses, neither volumetric parameters, including total tumor volume and organ-specific tumor volume, nor SUV values (SUVmax and SUVmean) were robust predictors of overall survival. K‒M and Cox regression analyses revealed no significant differences in survival between the high- and low-risk groups for these parameters. Furthermore, radiomics features extracted from liver metastases did not demonstrate significant prognostic value.</p><p><strong>Conclusion: </strong>Quantification of ⁶⁸Ga-DOTATOC PET/CT-derived parameters offers limited prognostic value for OS in NET patients who are receiving PRRT in clinical practice. These findings might emphasize the current robust integration of imaging in clinical decision-making for NET management.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"81"},"PeriodicalIF":3.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ΔSUVmax adds prognostic value to early response assessment during the first-line treatment of classical hodgkin lymphoma: a retrospective cohort study.","authors":"László Imre Pinczés, Dávid Tóthfalusi, Boglárka Dobó, Sándor Barna, Bence Farkas, Ildikó Garai, Árpád Illés, Zsófia Miltényi","doi":"10.1186/s40644-025-00904-x","DOIUrl":"10.1186/s40644-025-00904-x","url":null,"abstract":"<p><strong>Background: </strong>In classical Hodgkin lymphoma (HL), optimizing early risk stratification and response assessment are the cornerstones of therapy. The advanced interpretation of positron emission tomography - computed tomography (PET/CT) results can provide prognostic information beyond the Deauville score (DS). The aim of our study was to explore the prognostic value of the change in maximum standardized uptake value (ΔSUVmax) to predict disease progression during the first-line treatment of adult HL.</p><p><strong>Methods: </strong>All patients were treated with curative intent, standard therapy. PET/CT assessments were performed at baseline, interim and end-of-treatment timepoints. ΔSUVmax cut-off values were determined by the receiver operating characteristics (ROC) analysis. Overall- (OS) and progression-free survival (PFS) were determined as primary endpoints.</p><p><strong>Results: </strong>Baseline SUVmax did not differ in patients who progressed during or after first-line therapy compared to patients in remission. However, patients with progressive disease had a higher mean SUVmax and lower ΔSUVmax at interim analysis. The presence of a ΔSUVmax > 88% after 2 cycles of therapy was associated with longer PFS (P = 0.013 [HR, 5.21]), with a negative predictive value exceeding the DS. The combination of ΔSUVmax with DS further stratified PET-negative patients: the 5-year PFS of low-risk and high-risk patients were 92.1% and 79.1%, respectively (P = 0.047 [HR, 2.87]). The ΔSUVmax cut-off of 55% in patients with DS 3-5 revealed high-risk patients with significantly lower 5-year OS and PFS (P = 0.008 [HR, 13] and P < 0.001 [HR, 11.5], respectively).</p><p><strong>Conclusions: </strong>Altogether, ΔSUVmax is a promising standalone prognostic marker or combination partner of DS in the early risk stratification and response assessment of HL.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"80"},"PeriodicalIF":3.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT delta-radiomics predicts the risks of blood transfusion and massive bleeding during spinal tumor surgery.","authors":"Suwei Liu, Yali Li, Shuai Tian, Chenyu Jiang, Ming Ni, Ke Xu, Feng Wei, Huishu Yuan","doi":"10.1186/s40644-025-00900-1","DOIUrl":"10.1186/s40644-025-00900-1","url":null,"abstract":"<p><strong>Background: </strong>Intraoperative bleeding is a serious complication of spinal tumor surgery. Preoperative identification of patients at high risk of intraoperative blood transfusion (IBT) and intraoperative massive bleeding (IMB) before spinal tumor resection surgery is difficult but critical for surgical planning and blood management. This study aims to develop and validate delta radiomics prediction models for IBT and IMB in spinal tumor surgery.</p><p><strong>Methods: </strong>Patients diagnosed with spinal tumors who underwent spinal tumor resection surgery were retrospectively recruited. CT, CTE, delta, and clinical models based on CT native phase, CT arterial phase images, and clinical factors were constructed using 10-fold cross-validation and logistic regression (LR), random forest (RF), and support vector machine (SVM) in the training cohort. Receiver operating characteristic (ROC) curves, integrated discrimination improvement (IDI), accuracy, sensitivity, specificity, positive predictive value, and negative predictive value were used to evaluate and compare the diagnostic performance of these models.</p><p><strong>Results: </strong>231 patients were randomly divided into training (n = 161) and test (n = 70) cohorts, comprising 146 IBT and 85 no-IBT patients, 35 IMB and 196 no-IMB patients, respectively. The delta model performed best in predicting IBT and IMB risk, with better predictive ability than the clinical model (IDI = 0.11-0.13 for IBT, and IDI = 0.02-0.08 for IMB, p < 0.05, respectively). Calibration curves indicated that the predicted probabilities of IBT and IMB in the model did not differ significantly from the actual probabilities (p > 0.05).</p><p><strong>Conclusion: </strong>The CT delta model we constructed may be a valuable tool to improve risk stratification before spinal tumor surgery, thus contributing to preoperative planning and improving patient prognosis.</p><p><strong>Trial registration: </strong>Retrospectively registered (M2020435).</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"79"},"PeriodicalIF":3.5,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety in synchronous core-needle biopsy and cryoablation for highly suspicious malignant pulmonary nodule.","authors":"Tongyin Zhang, Qiaoyu Xu, Yuwan Hu, Haoyu Li, Haoran Du, Zhenguo Huang, Sheng Xie, Meng Yang, Yanyan Xu, Hongliang Sun","doi":"10.1186/s40644-025-00901-0","DOIUrl":"10.1186/s40644-025-00901-0","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous computed tomography (CT)-guided biopsy and cryoablation are commonly used techniques for diagnosing and treating pulmonary malignant tumors. Performing these procedures simultaneously allows for tissue diagnosis while potentially offering therapeutic benefits. This study aimed to evaluate whether the efficacy and safety of simultaneous percutaneous CT-guided biopsy and cryoablation in managing pulmonary tumors suspected of malignancy are comparable to those of sequential procedures.</p><p><strong>Methods: </strong>This retrospective study involved 124 patients with 131 highly suspicious malignant pulmonary nodules. Patients either underwent synchronous percutaneous core-needle biopsy and cryoablation (Group A) or separately underwent these procedures (Group B) from December 2020 to May 2024. All procedures were performed under CT guidance using a percutaneous approach. We analyzed technical success rates, complications, diagnostic yield, and local tumor control.</p><p><strong>Results: </strong>Technical success rates were 100% in both groups. The rate of pneumothorax was 42.1% (16/38) in Group A and 34.9% (30/86) in Group B. In Group A, hemoptysis and pleural effusion rates were 18.4% (7/38) and 23.7% (9/38), respectively, while in Group B, these rates were 16.3% (14/86) and 12.8% (11/86). These differences were not statistically significant. The diagnostic positive rate in Group A was 87.5%. The mean follow-up duration was 11.8 months (95% confidence interval [CI], 10.2-13.4), with local tumor control rates of 97% for Group A and 88% for Group B. The effectiveness rates of synchronous and separate procedures were similar.</p><p><strong>Conclusion: </strong>Synchronous biopsy-ablation is an effective method for obtaining tumor pathology and local treatment of lung tumors simultaneously. It is a viable option for select patients where expedited diagnosis-therapy is clinically justified, particularly when molecular profiling is not immediately indicated.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"78"},"PeriodicalIF":3.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thermal ablation for pulmonary oligometastases from hepatocellular carcinoma: initial experience and retrospective study.","authors":"Rongna Hou, Xueliang Zhou, Yipu Li, Yamin Qin, Mengyao Song, Chengzhi Zhang, Zhanguo Sun, Dechao Jiao","doi":"10.1186/s40644-025-00896-8","DOIUrl":"10.1186/s40644-025-00896-8","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the long-term efficacy of thermal ablation in the treatment of pulmonary oligometastases (POs) from hepatocellular carcinoma (HCC) and to explore the prognosis-related influencing factors.</p><p><strong>Methods: </strong>From October 2012 to January 2019, 145 POs (mean diameter: 2.3 cm, ≤ 4 POs per patient) in 62 patients (male = 33, female = 29, mean age: 61.0 years old) with HCC were treated by thermal ablation. The primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoints were technical success, technical efficacy, and complications. PFS and OS were analyzed by the log-rank test and Cox proportional hazards regression models.</p><p><strong>Results: </strong>Technical success, technical efficacy and major complications were 100, 96.8, and 21%, respectively. During the median follow-up of 30 months (range: 16-50), the median PFS was 11.4 months (95% CI 10.1-12.8), the 1- and 2-year PFS rates were 43.5 and 10.2%, respectively, and radical treatments for primary HCC (P < 0.01), metachronous POs (P < 0.01) and initial Barcelona Clinic Liver Cancer (BCLC) stage 0-B (P < 0.05) were significant indicators of superior PFS. The mOS was 33.0 months (95% CI 26.9-39.1), and the 1-, 2- and 3-year OS rates were 98.4, 78.7% and 43.7%, respectively. Radical treatments for primary HCC (P < 0.01) and initial BCLC stage 0-B (P < 0.05) showed superior OS.</p><p><strong>Conclusion: </strong>POs ablation after primary HCC control is safe and effective, and initial BCLC stage evaluation and radical treatment strategies should be emphasized. This study has certain limitations, including the retrospective design, single-center data, selection bias and small sample size.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"76"},"PeriodicalIF":3.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}